Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen (Q84864312)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 October 2009

Language	Label	Description	Also known as
English	Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen	scientific article published on 13 October 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

mucopolysaccharidosis VI

1 reference

based on heuristic

inferred from title

3

object named as

Joleen White

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

9

object named as

John J Hopwood

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Dyane Auclair

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

John Finnie

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Timothy Nielsen

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Maria Fuller

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Emil Kakkis

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Alphonsus Cheng

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Charles A O'Neill

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

13 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Molecular Genetics and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

99

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

132-141

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Bone-Marrow Transplantation in the Maroteaux–Lamy Syndrome (Mucopolysaccharidosis Type VI)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-ac

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Neurosurgical interventions in children with Maroteaux-Lamy syndrome. Case report and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Myelopathy due to diffuse thickening of the cervical dura mater in Maroteaux-Lamy syndrome: report of a case

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Compressive myelopathy associated with type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Compressive myelopathy in Maroteaux-Lamy syndrome: clinical and pathological findings

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Myelography Features of Mucopolysaccharidoses: A New Sign

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Myelopathy associated with Maroteaux-Lamy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Magnetic resonance imaging in the diagnosis of the cranio-cervical manifestations of the mucopolysaccharidoses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Lysosomal storage diseases and the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Mutational analysis of 105 mucopolysaccharidosis type VI patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Feline mucopolysaccharidosis type VI. Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Determination of monosaccharides and disaccharides in mucopolysaccharidoses patients by electrospray ionisation mass spectrometry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Immune response to enzyme replacement therapy: 4-sulfatase epitope reactivity of plasma antibodies from MPS VI cats

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Immunochemical characterization of feline and human N-acetylgalactosamine 4-sulfatase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Monitoring dose response of enzyme replacement therapy in feline mucopolysaccharidosis type VI by tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Complications of interlaminar cervical epidural steroid injections: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Cervical epidural steroid injection with intrinsic spinal cord damage. Two case reports

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2009.10.002

7 January 2021

Identifiers

10.1016/J.YMGME.2009.10.002

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19896877%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84864312&oldid=1871029416"